Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 27:14:05026.
doi: 10.7189/jogh.14.05026.

The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran

Mahya Razimoghadam  1 , Rajabali Daroudi  1   2 , Mehdi Yaseri  3
Affiliations

The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran

Mahya Razimoghadam et al. J Glob Health. .

Abstract

Background: The pandemic of the coronavirus disease 2019 (COVID-19) led to a global health crisis, prompting widespread vaccination efforts to reduce severe outcomes. In this study, we assessed the impact of mass COVID-19 vaccination on hospitalisation and mortality rates in Iran, where over 83% of the vaccinated population received inactivated virus vaccines.

Methods: Using retrospective, cross-sectional analysis, we examined data from the Iran Health Insurance Organisation, covering 41 million individuals from 20 February 2020 to 20 March 2022. We analysed hospital records from 956 Iranian hospitals, focusing on inpatient stays, short-term hospitalisations, and emergency department visits. Study outcomes included COVID-19 hospital admissions and associated mortality. We used negative binomial regression to compare hospital admission rates between periods, while we used a poison regression model with a log link to assess mortality risks before and after vaccination.

Results: Among 806 076 hospital admissions, 57 599 deaths were recorded. COVID-19 hospitalisations increased with age, and women had slightly higher admission rates than men. Advanced age and male sex correlated with higher mortality rates. Hospital admissions rose to 1178.66 per million population per month post-vaccination compared to 459.78 pre-vaccination. The incidence rate ratio was 2.09 (95% confidence interval (CI) = 1.90-2.32, P < 0.001), mainly due to the Delta variant. In contrast, post-vaccination mortality rates decreased from 111.33 to 51.66 per 1000 admissions per month. Post-vaccination, COVID-19 mortality significantly decreased, with a relative risk being 0.61 (95% CI = 0.60-0.62, P < 0.001) across all age groups and sexes.

Conclusions: The Delta variant increased hospital admissions among vaccinated individuals, but widespread vaccination significantly reduced COVID-19-related mortality.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.

Figures

Figure 1
Figure 1
COVID-19 hospital admissions, in-hospital deaths, and people vaccinated per 100 with at least one dose during the pandemic, with SARS-CoV-2 clades indicated for each time frame.
Figure 2
Figure 2
Incidence rate ratio of COVID-19 hospital admissions after vaccination compared to the pre-vaccination period as the baseline in Iran. *Significant P-values (P < 0.05).
Figure 3
Figure 3
Comparison of COVID-19 in-hospital mortality risk per 1000 admissions per month between pre- and post-vaccination periods.
Figure 4
Figure 4
The relative risk of COVID-19 in-hospital mortality after vaccination compared to the pre-vaccination period as the baseline. All P-values are statistically significant (P < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization. WHO coronavirus (COVID-19) dashboard. 2024. Available: https://data.who.int/dashboards/covid19/cases?n=c. Accessed: 4 September 2024.
    1. Jara A, Undurraga EA, Flores JC, Zubizarreta JR, González C, Pizarro A, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. Lancet Reg Health Am. 2023;21:100487. 10.1016/j.lana.2023.100487 - DOI - PMC - PubMed
    1. Wichaidit M, Nopsopon T, Sunan K, Phutrakool P, Ruchikachorn P, Wanvarie D, et al. Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: A prospective cohort study. Lancet Reg Health Southeast Asia. 2023;8:100106. 10.1016/j.lansea.2022.100106 - DOI - PMC - PubMed
    1. Santos CVBD, Noronha TG, Werneck GL, Struchiner CJ, Villela DAM.Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: A retrospective observational study. Lancet Reg Health Am. 2023;17:100418. 10.1016/j.lana.2022.100418 - DOI - PMC - PubMed
    1. Ferreira LS, Darcie Marquitti FM, Paixão da Silva RL, Borges ME, Ferreira da Costa Gomes M, Cruz OG, et al. Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis. Lancet Reg Health Am. 2023;17:100397. 10.1016/j.lana.2022.100397 - DOI - PMC - PubMed

MeSH terms

Substances